Virogin awarded 2018 Ernst & Young Fudan China’s Most Promising Enterprise

October 16, 2018
Virogin Biotech Ltd.

Shanghai, China – Virogin Biotech Ltd. (“Virogin”) has been named 2018 Ernst & Young Fudan China’s Most Promising Enterprise, recognized within the ‘Health Reimagined’ category. Hosted by global professional services firm Ernst & Young and Fudan University’s School of Management, these 8th annual awards identified prominent companies and future industry leaders that exhibit a commitment … Continue reading Virogin awarded 2018 Ernst & Young Fudan China’s Most Promising Enterprise

Augurex and Quidel at ACR

Augurex Life Science Corp.

Augurex and Quidel are pleased to announce the launch of the JOINTstat® 14-3-3η RUO (research use only) ELISA. This new distribution arrangement will get 14-3-3η testing into the hands of more investigators worldwide, including key opinion leaders and pharmaceutical companies, to advance and grow the body of data for this novel joint damage biomarker in … Continue reading Augurex and Quidel at ACR

CDRD Appoints Didier Leconte to its Board of Directors

October 15, 2018
The Centre for Drug Research and Development

October 15, 2018 Vancouver, Canada: CDRD – The Centre for Drug Research and Development, Canada’s national life sciences venture, is pleased to announce the appointment of Mr. Didier Leconte as a new Director of the organization. Mr. Leconte is Vice-President, Investments – Life Sciences with the Fonds de solidarité FTQ, which he first joined in … Continue reading CDRD Appoints Didier Leconte to its Board of Directors

GenXys selected to present at the Healthcare Revolution conference in Orlando, Florida

GenXys

We are thrilled to be selected to present our leading precision prescribing solution at the Healthcare Revolution conference in Orlando, Florida on October 28th, 2018. Global Healthcare Ventures joined forces with Global Healthcare Resources to showcase companies with high-growth market potential. Location: Orange County Convention Center | Orlando, FL Booth #807 Book a meeting with … Continue reading GenXys selected to present at the Healthcare Revolution conference in Orlando, Florida

DelMar Announces Further Validation of the Mechanism of Action of VAL-083

October 11, 2018
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 10, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the publication of a peer-reviewed scientific paper on the mechanism of action for VAL-083, the Company’s product candidate, in Cell Death and … Continue reading DelMar Announces Further Validation of the Mechanism of Action of VAL-083

Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer

October 9, 2018
Arbutus Biopharma Corporation

Dr. Mark Murray, Arbutus President & Chief Executive Officer, to participate in a fireside chat at Chardan’s Genetic Medicines Conference at 2:45 pm ET today WARMINSTER, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a change to its executive leadership team and provided an … Continue reading Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer

Finland Company Terveystekniikka Oy to Participate in I love me 2018 Health Expo with WAT Med’s Signature Medical Devices

WAT Medical Inc.

VANCOUVER, British Columbia, Oct. 5, 2018 /PRNewswire/ — Terveystekniikka Oy, a strategic partner of WAT Medical Enterprise Ltd. (WAT Med), will participate in “I love me 2018”, the biggest health expo of Finland held from October 19-21, 2018. HeadaTerm and EmeTerm, sigature medical devices developed by WAT Med, will be promoted during the expo. As import agents of … Continue reading Finland Company Terveystekniikka Oy to Participate in I love me 2018 Health Expo with WAT Med’s Signature Medical Devices

Arbutus to Present at Chardan’s Genetic Medicines Conference

October 2, 2018
Arbutus Biopharma Corporation

WARMINSTER, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 2:45 pm – 3:10 pm ET in New York. A live webcast of the fireside chat can be accessed through … Continue reading Arbutus to Present at Chardan’s Genetic Medicines Conference

Financing will accelerate AbCellera’s therapeutic antibody discovery business.

AbCellera

Vancouver, Canada (September 27, 2018) – AbCellera announced today that it has closed its Series A financing led by DCVC Bio, a Silicon Valley venture capital fund focused on deep technology ventures that lie at the nexus of artificial intelligence and biotechnology. AbCellera will use the USD $10 million financing to accelerate the growth of … Continue reading Financing will accelerate AbCellera’s therapeutic antibody discovery business.

DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results

September 24, 2018
DelMar Pharmaceuticals, Inc.

Company will host a business update conference call on September 25, 2018 at 4:30 PM Eastern Time  VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 24, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc.(NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended … Continue reading DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results